Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma Álvaro Pinto Review Article 08 November 2013 Pages: 219 - 222
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib Hidenari NagaiTakenori KanekawaYasukiyo Sumino Original Article 13 November 2013 Pages: 223 - 229
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer M. KrzakowskiJ. BennounaJ. M. Tourani Original Article Open access 13 November 2013 Pages: 231 - 236
Antitumor effects of BI-D1870 on human oral squamous cell carcinoma Chang-Fang ChiuLi-Yuan BaiJing-Ru Weng Original Article 16 November 2013 Pages: 237 - 247
A phase I trial of flavopiridol in relapsed multiple myeloma Craig C. HofmeisterMing PoiJohn C. Byrd Original Article 16 November 2013 Pages: 249 - 257
Vascular-targeted agents for the treatment of angiosarcoma R. J. YoungP. J. WollN. J. Brown Original Article 20 November 2013 Pages: 259 - 270
p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma Veena R. GaneshanNina F. Schor Original Article 20 November 2013 Pages: 271 - 279
Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer Takashi KosakaHirotoshi AkiyamaItaru Endo Original Article 20 November 2013 Pages: 281 - 285
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS) Emilie HéninBenoit BlanchetMichel Tod Original Article 20 November 2013 Pages: 287 - 297
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib Marcello TiseoMassimo IppolitoHector J. Soto Parra Original Article 21 November 2013 Pages: 299 - 307
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer Hidetoshi EguchiHiroaki NaganoYuichiro Doki Original Article 21 November 2013 Pages: 309 - 315
Mechanisms affecting neutrophil migration capacity in breast cancer patients before and after chemotherapy Maria Angélica Oliveira MendonçaFabrício O. SoutoBeatriz M. Tavares-Murta Original Article 21 November 2013 Pages: 317 - 324
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer Qun ZhangJie ShenXiaoping Qian Original Article 27 November 2013 Pages: 325 - 333
Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy Chaohui WuMinjie LiHongbing Duan Original Article 28 November 2013 Pages: 335 - 341
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors Woondong JeongAnnamaria RapisardaShivaani Kummar Original Article 30 November 2013 Pages: 343 - 348
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose Katherine B. PhilipsMetin KurtogluTheodore J. Lampidis Original Article 01 December 2013 Pages: 349 - 361
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors Anthony W. TolcherWendi V. RodriguezaRichard A. Messmann Original Article Open access 03 December 2013 Pages: 363 - 371
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer Muhammad Wasif SaifJia LiYung-Chi Cheng Original Article 03 December 2013 Pages: 373 - 380
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation Yi Ling TeoXue Jing ChongAlexandre Chan Original Article 04 December 2013 Pages: 381 - 388
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer Kentaro SudoTakeshi IshiharaTaketo Yamaguchi Original Article 10 December 2013 Pages: 389 - 396
Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo Zhongyi HuDenglu ZhangHuiqing Yuan Original Article 10 December 2013 Pages: 397 - 407
CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy Yukiya NaritaHiroya TaniguchiKei Muro Original Article 10 December 2013 Pages: 409 - 416
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors Elizabeth J. SullivanMetin KurtogluTheodore J. Lampidis Original Article 19 December 2013 Pages: 417 - 427
Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report L. L. KrensJ. M. BaasH. Gelderblom Short Communication 21 November 2013 Pages: 429 - 433
Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine Hans-Peter LippWieland Gfrörer Commentary 13 November 2013 Pages: 435 - 436
Reply to: assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine Brett Duersch Letter to the Editor 07 January 2014 Pages: 437 - 437